cisplatin,carboplatin,avelumab,domvanalimab,zimberelimab,sacituzumab govitecan,gemcitabine,pembrolizumab,enfortumab vedotin
merck,astellas,otsuka,gilead sciences,pfizer,gilead,seagen,arcus biosciences
['muc ,(-much)', 'avelumab', 'pembro', 'cisplatin', 'sacituzumab', 'urothelial', ' sg ', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'tropics-04', ' cis ', 'trophy,u-01', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'sacitu, govi', 'carboplatin', 'ev-302', ' gem ', 'gemcitabine', 'zimberelimab', 'domvana', ' uc,(-ucsd),(-ucsf),']
#gu23 trophy-u-01 cohort 2 of sg in plat-ineligible, post io muc: n=38, orr 32% (pr), 18% primary gcsf. ongoing adc : which payloads, when; sequencing / cross resistance; which combos; earlier better? 1l sg data of interest, in anticipation of ev-302 
Medical Oncologist, @HamHealthSci | Assistant Professor, @McMasterU | Former Fellow, @DanaFarber | Academic focus: genitourinary & rare cancers | Views my own.